Zostavax
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Immune System Diseases
Conditions
Immune System Diseases
Trial Timeline
May 1, 2011 → Mar 1, 2015
NCT ID
NCT01328548About Zostavax
Zostavax is a pre-clinical stage product being developed by Merck for Immune System Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT01328548. Target conditions include Immune System Diseases.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01391546 | Phase 3 | Completed |
| NCT01328548 | Pre-clinical | Completed |
| NCT00561080 | Phase 3 | Completed |
Competing Products
20 competing products in Immune System Diseases